EVOK News and Press, Evoke Pharma Inc. From 03/30/21

SOLANA BEACH, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a commercial stage specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that Yale Jen, Senior Biotech Analyst at Laidlaw & Comp...

Gainers: NLS Pharmaceutics (NLSP) +87%.Entera Bio (ENTX) +72%.Seelos Therapeutics (SEEL) +69%.Ebang International (EBON) +43%.Perpetua Resources (PPTA) +27%.AMREP (AXR) +21%.22nd Century (XXII) +19%.Aemetis (AMTX) +18%.LendingClub (LC) +18%.MicroVision (MVIS) +17%.Losers: Marker The...

Evoke Pharma (EVOK) shares plummeted 29% after-hours after the company released its Q4 earnings.For Q4, net sales were  approx. $23K.Net loss was ~$2.3M, or $0.09 per share, compared to a net loss of ~$1.4M, or $0.06 per share.This increase in net loss was primarily due to $5M ...

Evoke Pharma, Inc. (EVOK) Q4 2020 Results Conference Call March 11, 2021 04:30 PM ET Company Participants Dave Gonyer - Chief Executive Officer Matt D’Onofrio - Chief Business Officer Chris Quesenberry - Chief Commercial Officer, Eversana Conference Call Participants Yale Jen - Laidlaw...

Evoke Pharma (EVOK): Q4 GAAP EPS of -$0.09 beats by $0.05.Revenue of $0.02MAs of December 31, 2020, the Company’s cash and cash equivalents were approximately $8.1 million, which excludes approximately $13.1 million in net proceeds raised from our common stock offering in January 2021....

SOLANA BEACH, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter ended December 31, 2020 and recent ...

SOLANA BEACH, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that the Company is scheduled to release its fourth quarter and full year 20...

Evoke Pharma finally received FDA approval for Gimoti, a nasal formulation of a generic GI drug, in June 2020 and launched the drug in October 2020. Post-approval, the stock price decreased as investors' dreams of the company being acquired faded, and the reality of a small company dr...

SOLANA BEACH, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, announced today the completion of its follow-on offering of 5,750,000 shares of its common st...

Evoke Pharma (EVOK) has priced its public offering of 5M common shares at $2.50/share, for estimated gross proceeds of $12.5M.Underwriter's over-allotment is an additional 750K shares. Net proceeds will be used for working capital and general corporate purposes.Laidlaw & Company is acting...